

Metaanalysis on effects of cardiac resynchronization therapy in heart failure patients with narrow QRS complex

Vinodh Jeevanantham¹, Wojciech Zareba², Sankar Navaneethan², David Fitzgerald¹,
Cheuk-Man Yu³, Augusto Achilli⁴, Jeroen Bax⁵ and James Daubert²

¹Wake Forest University Medicine Winston, Salem, USA

²University of Rochester Cardiology, Rochester, USA

³The Chinese University of Hong Kong Cardiology, Hong Kong, China

⁴Belcolle Hospital Cardiology, Viterbo, Italy

⁵Leiden University Medical Center Cardiology, Leiden, The Netherlands

Abstract

Background: *To systematically review the benefits of cardiac resynchronization therapy (CRT) in heart failure patients with narrow QRS (< 120 ms) who have baseline mechanical asynchrony.*

Methods: *We searched the MEDLINE, Cochrane Central Register of Controlled Trials, and reference lists of retrieved articles for relevant trials through October 2007. Studies were included if they were clinical trials in heart failure patients with narrow QRS complex, had at least 3 months of duration and measured baseline mechanical dyssynchrony. Weighted mean difference (WMD) for changes in left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) class and 6 minute walk distance (6MWD) at the end of follow up period were estimated using fixed effects meta-analysis.*

Results: *Three relevant clinical trials (enrolling 98 patients) out of 80 identified studies were included in the final analysis. When compared to baseline, CRT in heart failure patients with narrow QRS complex significantly improved mean LVEF (WMD 7.98%, 95% CI 5.94, 10.03) and 6MWD (WMD 67 m, 95% CI 39.12, 94.98) at the end of follow up period with no significant heterogeneity between the included studies ($P < 50\%$). Similarly, there was a significant reduction in NYHA at the end of follow-up (WMD -0.87 , 95% CI -1.01 , -0.74) but there was significant heterogeneity between the included studies.*

Conclusions: *In patients with narrow QRS complex and baseline mechanical asynchrony, who underwent CRT after optimal medical management, there was a significant reduction in NYHA class, improvement in LVEF and increase in 6MWD during follow up. Further data from large randomized trials are warranted to explore the role of CRT in heart failure patients with narrow QRS complex. (Cardiol J 2008; 15: 230–236)*

Key words: cardiac resynchronization therapy, heart failure, narrow QRS

Address for correspondence: Vinodh Jeevanantham, MD, MPH, General Internal Medicine, Wake Forest University Health Sciences, Medical Center Blvd, Winston-Salem, NC-27157, tel: 336 716 8212, fax: 336 716 7359, e-mail: vjeevanantham@gmail.com

Received: 21.04.2008

Accepted: 7.05.2008

Introduction

About 5 million people in United States currently have heart failure [1, 2]. Each year about 550,000 patients are newly diagnosed with heart failure and about 287,000 deaths occur each year which are attributable to heart failure [1, 2]. Hospitalizations due to heart failure are increasing [1, 3, 4] and this is especially true with the aging population [3, 5]. In 2006, the estimated direct cost for heart failure in United States was \$ 29.6 billion dollars [1, 2].

In patients with wide QRS (> 120 ms), cardiac resynchronization therapy (CRT) has been shown to facilitate reverse remodeling of the left ventricle leading to increased left ventricular ejection fraction, reduced mitral regurgitation and reduced heart size [6]. Several trials have shown that CRT in patients with wide QRS improved quality of life, improved exercise tolerance, and 6 min walking distance [7–12]. More importantly, clinical trials [13, 14] and meta-analyses [15–18] have shown that CRT decreases mortality in heart failure patients with wide QRS complex.

However non-response rate to CRT in heart failure patients with wide QRS complex is reported up to 30% [19]. Baseline QRS duration has been found to be a poor predictor of clinical and echocardiographic responses to CRT [20]. Clinically it is often difficult to predict who will respond to the CRT. Therefore, there is a need to explore other possible factors that might play a role to get better response to CRT. Left ventricular mechanical asynchrony is one such factor which has been recently shown to predict prognosis in patients with CRT [21–23]. Recent studies have also shown that there is a high prevalence of left ventricular mechanical asynchrony in patients with narrow QRS (< 120 ms) [24]. Only few clinical trials have looked at the benefit of CRT in patients with narrow QRS [25–31]. Since there is a high prevalence of left ventricular asynchrony in heart failure patients with narrow QRS complexes, and there is a need to explore the role of CRT in these group of patients, we aimed to systematically review the benefits of CRT in heart failure patients with narrow QRS who have baseline mechanical asynchrony.

Methods

Search strategy

We searched MEDLINE and the Cochrane Controlled Trials Register in October 2007 for clinical trials of CRT in heart failure patients with narrow

QRS complex using the appropriate terms: cardiac resynchronization therapy, heart failure, congestive heart failure, pacemaker, narrow QRS complex.

Study selection/data extraction

Two investigators independently screened all titles and abstracts to identify the studies which looked at benefits of CRT in patients with narrow QRS complex and heart failure. One of these reviewers extracted relevant data using a standardized data extraction from the included studies. Disagreements were resolved by discussion with James P. Daubert. Both randomized and non-randomized studies with a follow-up period of at least 3 months were considered for inclusion. Changes in left ventricular ejection fraction (LVEF), NYHA class and 6 minute walk distance (6MWD) at the end of follow up period were the primary outcome measures. Studies were excluded if the effects of CRT were not reported separately from CRT with implantable cardioverter defibrillator (ICD).

Statistical analysis

Statistical analyses were performed using the Cochrane Revman software 4.2.8 and the results were expressed as weighted mean difference (WMD) for continuous outcomes, with 95% confidence intervals (95% CI) using fixed effects model. We planned to conduct sensitivity analyses if significant heterogeneity was found (I^2) for any one of the outcomes.

Results

Search results

Three relevant clinical trials (enrolling 98 patients) out of 80 studies were included in the final analysis (Fig. 1). The trials included in this meta-analysis for narrow QRS studies were reported by Yu et al. [25], Bleeker et al. [26] and Achilli et al. [28], two trials Turner et al. [29] and Gasparini et al. [31] were excluded as these studies did not measure baseline LV dyssynchrony. The baseline characteristics of the studies included in meta-analysis for narrow QRS are shown in Table 1 and 2. Primary outcomes of the studies included are shown in Table 3.

Left ventricular ejection fraction

When compared to baseline, CRT in patients with narrow QRS complex improved mean LVEF (3 studies, 98 patients, WMD 7.98%, 95% CI 5.94, 10.03) without any significant heterogeneity between the included studies ($\chi^2 = 0.41$, $p = 0.82$, $I^2 = 0\%$) (Fig. 2).




Figure 1. Study Selection from MEDLINE search.

Six minute walk distance (6MWD)

In comparison to baseline, CRT in patients with narrow QRS complex increased the 6MWD significantly (3 studies, 98 patients, WMD 67 m, 95% CI 39.12, 94.98) at the end of follow up period with no

heterogeneity between the included studies ($\chi^2 = 2.8, p = 0.24, I^2 = 30.3\%$) (Fig. 3).

Change in NYHA classification

There was a significant reduction in NYHA at the end of follow-up period with CRT in patients with narrow QRS complex (3 studies, 98 patients, WMD $-0.87, 95\% \text{ CI } -1.01, -0.74$) with significant heterogeneity between the included studies ($\chi^2 = 15.18, p = 0.0005, I^2 = 86.8\%$) (Fig. 4).

Sensitivity analysis

Heterogeneity was explored through sensitivity analyses and the exclusion of the trial by Achilli et al. [28] eliminated the heterogeneity for change in NYHA. This is probably related to the smaller sample size in this study compared to the other two studies included in the analyses.

Discussion

Our meta-analysis showed that there was a significant improvement in mean LVEF and 6MWD at the end of follow up period. Similarly, there was a significant reduction in NYHA at the end of follow-up period. These results suggest that there is a potential role of CRT in narrow QRS complex heart failure patients.

Table 1. Baseline characteristics of studies included in the meta-analysis.

Study	Objective	Study duration (months)/ /No. of patients	Outcomes analyzed	Findings
Bleeker et al. [26]	Role of CRT in HF patients with narrow QRS (<120 ms) and echocardiographic evidence of baseline asynchrony	6/33	1. Reduction in NYHA class 2. Improvement in 6MWD 3. Improvement in LVEF (%) 4. Improvement in QoL 5. Reduction in LVESV 6. Reduction in LVEDV	Significant improvement of NYHA functional class, improvement in 6MWD, improvement in LVESV
Yu et al. [25]	Effects of CRT in HF patients with narrow QRS (< 120 ms) and evidence of baseline asynchrony on tissue Doppler imaging	3/51	1. Reduction in NYHA class 2. Improvement in 6MWD 3. Improvement in LVEF (%) 4. Improvement in QoL 5. Reduction in LVESD 6. Reduction in LVEDD	Significant improvement of NYHA functional class, improvement in 6MWD, improvement in LVESD, Reduction in mitral regurgitation area
Achilli et al. [28]	Effects of CRT in refractory HF patients with narrow QRS (< 120 ms) and evidence of baseline asynchrony on echocardiography	6/14	1. Reduction in NYHA class 2. Improvement in 6MWD 3. Improvement in LVEF (%) 4. Reduction in LVESD 5. Reduction in LVEDD	Significant improvement of NYHA functional class, improvement in 6MWD, improvement in LVESD, reduction in mitral regurgitation area

CRT — cardiac resynchronization therapy; HF — heart failure; NYHA — New York Heart Association heart failure class; QoL — quality of life; 6MWD — 6 min walk distance; LVEF — left ventricular ejection fraction; LVEDV — left ventricular end-diastolic volume; LVEDD — left ventricular end-diastolic diameter; LVESV — left ventricular end-systolic volume; LVESD — left ventricular end-systolic diameter

Table 2. Characteristics of trials included in meta-analysis.

Baseline characteristics	Bleeker et al. [26]	Yu et al. [25]	Achilli et al. [28]
Mean QRS	110 ± 8	103 ± 13	NA
Age (mean ± SD)	63 ± 11	63 ± 11	68.3 ± 8
Men	85%	78.4%	71%
Ischemic	70%	49%	29%
NYHA	3.1 ± 0.3	2.84 ± 0.46	3.4 ± 0.5
QoL	39 ± 18	28 ± 14	NA
6MWD [m]	274 ± 133	333 ± 96	276.4 ± 88.9
LVEF (%)	22 ± 6	27.8 ± 7	24.6 ± 5.0
LVEDV ¹ [cc]/LVEDD ² [mm]	216 ± 78 ¹	167 ± 47 ¹	71.8 ± 9.2 ²
LVESV ¹ [cc]/LVESD ² [mm]	174 ± 75 ¹	122 ± 42 ¹	61.4 ± 8.4 ²
Left ventricular dyssynchrony	102 ± 32	35.9 ± 14.0	NA
Diuretics	82%	96%	100%
ACEI	88%	92%	90%*
Beta-blocker	76%	67%	60%

NA — not available; NYHA — New York Heart Association heart failure class; QoL — quality of life; 6MWD — 6 min walk distance; LVEF — left ventricular ejection fraction; LVEDV — left ventricular end-diastolic volume; LVEDD — left ventricular end-diastolic diameter; LVESV — left ventricular end-systolic volume; LVESD — left ventricular end-systolic diameter; ACEI — angiotensin converting enzyme inhibitor; *including angiotensin receptor blockers

Table 3. Primary outcomes after cardiac resynchronization therapy at 6 months.

	Bleeker et al. [26]	Yu et al. [25]	Achilli et al. [28]
Reduction in NYHA	0.9 ± 0.6	0.73 ± 0.4	1.6 ± 0.1
Reduction in QoL	13 ± 16	8 ± 19	NA
Improvement 6MWD	89 ± 107	46 ± 88	93.5 ± 18.7
Improvement in LVEF (%)	8 ± 8	7.3 ± 6.3	9 ± 0.9
Reduction in LVEDV ¹ [cc]/LVEDD ² [mm]	26 ± 32 ¹	8.6 ± 14 ¹	6.2 ± 0.7 ²
Reduction in LVESV ¹ [cc]/LVESD ² [mm]	39 ± 34 ¹	17.1 ± 18.6 ¹	5.8 ± 0.2 ²
All cause mortality	9	NA	3/14
Sudden death	0	NA	1
Progressive heart failure deaths	8	NA	2
Noncardiac deaths	NA	NA	0
Hospitalizations	6	NA	NA

NA — not available; NYHA — New York Heart Association heart failure class; QoL — quality of life; 6MWD — 6 min walk distance; LVEF — left ventricular ejection fraction; LVEDV — left ventricular end-diastolic volume; LVEDD — left ventricular end-diastolic diameter; LVESV — left ventricular end-systolic volume; LVESD — left ventricular end-systolic diameter

Although the role of CRT in heart failure patients with wide QRS (> 120 ms) is established, about 30 to 40% of patients do not respond to treatment [19]. The usefulness of QRS duration as a selection criterion among these patients has been questioned. There is a need to identify other factors that might help improve outcomes among patients with CRT. Left ventricular asynchrony is an important factor which predicts prognosis in patients with CRT [21–23]. Some of the other reported predictors of non-response to CRT include ischemic heart disease, severe MR and LVEDD ≥ 75 mm [32]. Incidence of left ventricular

dyssynchrony in heart failure patients vary between 27% to 56% and one study which specifically looked at narrow QRS complex heart failure patients reported 33% of left ventricular dyssynchrony [33].

Only few studies have looked at the potential role of CRT in patients with narrow QRS [25–31]. CRT has been shown to improve hemodynamics in CHF patients with narrow QRS [34]. Similarly, our systematic review shows significant improvement in clinical and functional parameters in narrow QRS complex patients who had CRT when compared to their baseline.




Figure 2. Improvement in left ventricular ejection fraction in heart failure patients with narrow QRS and baseline asynchrony at follow up compared to baseline.




Figure 3. Improvement in 6 minute walk distance in heart failure patients with narrow QRS and baseline asynchrony at follow up compared to baseline.




Figure 4. Improvement in New York Heart Association class in heart failure patients with narrow QRS and baseline asynchrony at follow up compared to baseline.

Gasparini et al. [31] studied the long term effects of CRT in heart failure patients with QRS ≤ 120 ms. Patients in this study were not pre-selected by echocardiographic presence of dyssynchrony. When we included the data at 6 months follow up from Gasparini et al. [31] to other three trials, 6MWD increased significantly (4 studies, 143 patients, WMD 63 m, 95% CI 38.85, 87.12) at the end of follow up period with no heterogeneity. Similarly LVEF increased (4 studies, 143 patients, WMD 7.73%, 95% CI 6.00, 9.47) without any significant heterogeneity. Further Gasparini et al. [31] had follow up for 36 months. When we included data at 36 months follow up there was a greater increase in 6MWD and LVEF. This shows that we need more data from long term trials which would allow adequate time for left ventricular remodeling.

Limitations of the study

One of the major limitations of the study is that the included studies are pre and post CRT studies without any randomization and any control group. So there is a potential risk of bias. Further we were unable to analyze the potential mortality benefit of CRT in narrow QRS complex patients because the available trials did not have a control arm with optimal medical management. Thus, the results will need to be interpreted with caution.

Recently study by Beshai et al. [35] showed that CRT in heart failure patients with narrow QRS complex did not improve peak oxygen consumption, Minnesota living with heart failure scores, 6 min walk distance and left ventricular volume and ejection fraction at 6 months. Potential differences in these results could be due to the method of measurement of mechanical dyssynchrony and lack of documentation. Beshai et al. [35] used opposite wall delay method to measure mechanical dyssynchrony whereas asynchrony index was used by Yu et al. [25], maximum delay between peak systolic velocities among the 4 walls within the left ventricle using tissue Doppler imaging was used by Bleekar et al. [26] and intraventricular asynchrony was identified when $Q-LW > Q-E$ and $Q-LW > 9.9$ corrected units (c.u. = measured interval in ms/ $\sqrt{R-R}$ interval) by Achilli et al. [28].

Further from Gasparini's trial we know that the benefits are significantly higher with longer duration. Perhaps we need data from trials with longer duration. Another protocol for a randomized clinical trial in heart failure patients with narrow QRS complex patients has been released from University of Zurich [36]. The results of this trial along with results from ReThinQ [35] after a longer duration

of follow up would help us understand the role of CRT in narrow QRS heart failure patients.

Conclusions

In summary, CRT in heart failure patients with narrow QRS and baseline mechanical asynchrony significantly improves LVEF, 6MWD and NYHA compared to their baseline. Further larger randomized trials would be needed before we can draw definite conclusion about benefit of CRT in heart failure patients with narrow QRS complex.

Acknowledgements

The authors do not report any conflict of interest regarding this work.

References

1. http://www.cdc.gov/dhdsp/library/pdfs/fs_heart_failure.pdf.
2. American Heart Association. Heart Disease and Stroke Facts, 2006 Update. AHA, Dallas, Texas 2006.
3. An Aging World: 2001. Kevin Kinsella and Victoria A Velkoff. <http://www.census.gov/prod/2001pubs/p95-01-1.pdf>.
4. Roger VL, Weston SA, Redfield MM et al. Trends in heart failure incidence and survival in a community-based population. *JAMA*, 2004; 292: 344–350.
5. Administration of Aging: Statistics of Aging. <http://www.aoa.gov/prof/Statistics/statistics.asp>.
6. Jessup M, Brozena S. Medical progress: Heart failure. *N Engl J Med*, 2003; 348: 2007–2018.
7. Cazeau S, Leclercq C, Lavergne T et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. *N Engl J Med*, 2001; 344: 873–880.
8. Abraham WT, Fisher WG, Smith AL et al. Cardiac resynchronization in chronic heart failure. *N Engl J Med*, 2002; 346: 1845–1853.
9. Leclercq C, Walker S, Linde C et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. *Eur Heart J*, 2002; 23: 1780–1787.
10. Auricchio A, Stellbrink C, Sack S et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. *J Am Coll Cardiol*, 2002; 39: 2026–2033.
11. Young JB, Abraham WT, Smith AL et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD Trial. *JAMA*, 2003; 289: 2685–2694.
12. Higgins SL, Hummel JD, Niazi IK et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. *J Am Coll Cardiol*, 2003; 42: 1454–1459.
13. Cleland J, Daubert JC, Erdmann E et al. The Effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med*, 2005; 352: 1539–1549.
14. Bristow MR, Saxon LA, Boehmer J et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med*, 2004; 350: 2140–2150.

15. Bradley DJ, Bradley EA, Baughman KL et al. Cardiac resynchronization and death from progressive heart failure: A meta-analysis of randomized controlled trials. *JAMA*, 2003; 289: 730–740.
16. McAlister FA, Ezekowitz JA, Wiebe N et al. Systematic review: Cardiac resynchronization in patients with symptomatic heart failure. *Ann Intern Med*, 2004; 141: 381–390.
17. Rivero-Ayerza M, Theuns D, Garcia-Garcia HM, Boersma E, Simons M, Jordaens LJ. Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. *Eur Heart J*, 2006; 27: 2682–2688.
18. McAlister FA, Ezekowitz J, Hooton N et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. *JAMA*, 2007; 297: 2502–2514.
19. Birnie DH, Tang AS. The problem of non-response to cardiac resynchronization therapy. *Curr Opin Cardiol*, 2006; 21: 20–26.
20. Mollema SA, Bleeker GB, van der Wall EE, Schalij MJ, Bax JJ. Usefulness of QRS duration to predict response to cardiac resynchronization therapy in patients with end-stage heart failure. *Am J Cardiol*, 2007; 100: 1665–1670 (Epub 2007 Oct 24).
21. Yu CM, Lin H, Zhang Q, Sanderson JE. High prevalence of left ventricular systolic and diastolic asynchrony in patients with congestive heart failure and normal QRS duration. *Heart*, 2003; 89: 54–60.
22. Bax JJ, Bleeker GB, Marwick TH et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. *J Am Coll Cardiol*, 2004; 44: 1834–1840.
23. Pitzalis MV, Iacoviello M, Romito R et al. Ventricular asynchrony predicts a better outcome in patients with chronic heart failure receiving cardiac resynchronization therapy. *J Am Coll Cardiol*, 2005; 45: 65–69.
24. Santos JF, Parreira L, Madeira J et al. Predictors of response to cardiac resynchronization therapy—importance of left ventricular dyssynchrony. *Rev Port Cardiol*, 2006; 25: 569–581.
25. Yu CM, Chan YS, Zhang Q et al. Benefits of cardiac resynchronization therapy for heart failure patients with narrow QRS complexes and coexisting systolic asynchrony by echocardiography. *J Am Coll Cardiol*, 2006; 48: 2251–2257.
26. Bleeker GB, Holman ER, Steendijk P et al. Cardiac resynchronization therapy in patients with a narrow QRS complex. *J Am Coll Cardiol*, 2006; 48: 2243–2250 (Epub 2006 Nov 9).
27. Yu CM, Fung JW, Chan CK et al. Comparison of efficacy of reverse remodeling and clinical improvement for relatively narrow and wide QRS complexes after cardiac resynchronization therapy for heart failure. *J Cardiovasc Electrophysiol*, 2004; 15: 1058–1065.
28. Achilli A, Sassara M, Ficili S et al. Long-term effectiveness of cardiac resynchronization therapy in patients with refractory heart failure and „narrow” QRS. *J Am Coll Cardiol*, 2003; 42: 2117–2124.
29. Turner MS, Bleasdale RA, Vinereanu D et al. Electrical and mechanical components of dyssynchrony in heart failure patients with normal QRS duration and left bundle-branch block: impact of left and biventricular pacing. *Circulation*, 2004; 109: 2544–2549.
30. Gasparini M, Mantica M, Galimberti P et al. Beneficial effects of biventricular pacing in patients with a „narrow” QRS. *Pacing Clin Electrophysiol*, 2005; 28: 357–360.
31. Gasparini M, Regoli F, Galimberti P et al. Three years of cardiac resynchronization therapy: Could superior benefits be obtained in patients with heart failure and narrow QRS? *Pacing Clin Electrophysiol*, 2007; 30 (suppl. 1): S34–S39.
32. Turner MS, Bleasdale RA, Mumford CE, Frenneaux MP, Morris-Thurgood JA. Left ventricular pacing improves haemodynamic variables in patients with heart failure with a normal QRS duration. *Heart*, 2004; 90: 502–505.
33. Bleeker GB, Schalij MJ, Molhoek SG et al. Frequency of left ventricular dyssynchrony in patients with heart failure and a narrow QRS complex. *Am J Cardiol*, 2005; 95: 140–142.
34. Diaz-Infante E, Mont L, Leal J et al. SCARS Investigators. Predictors of lack of response to resynchronization therapy. *Am J Cardiol*, 2005; 95: 1436–1440.
35. Beshai JF, Grimm RA, Nagueh SF et al. RethinQ Study Investigators. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. *N Engl J Med*, 2007; 357: 2461–2471 (Epub 2007 Nov 6).
36. <http://www.escardio.org/bodies/associations/EHRA/news/Clinical-trial-Cardiac-Resynchronization-Therapy.htm>.